

On page 57, line 6, before “. Then”, please insert --(SEQ ID NO:11)--.

On page 63, line 20, before “(in”, please insert --(SEQ ID NO:12)--.

On page 65, line 31, before “(in”, please insert --(SEQ ID NO:12)--.

On page 66, line 2, before “and”, please insert --(SEQ ID NO:13)--.

On page 66, line 6, before “, and”, please insert --(SEQ ID NO:12)--.

[Signature]
Please insert the attached Sequence Listing (pages 1-4) at the end of the specification.

REMARKS

This paper is submitted in response to the Office communication mailed November 7, 2000. The communication provided that the application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 because the application does not contain a Sequence Listing. The communication identified sequences that should be included in the sequence listing. Applicants submit that several of these sequences are not required to be included in a sequence listing, e.g., “page 67 all references to DNA/RNA hybrids.”

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing.

The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: December 6, 2000

Elias J. Lambiris

Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123